Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study

NCT03245021 is registered in ClinicalTrials.gov with Dr. Eliza Hawkes as lead sponsor.

NCT NCT03245021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03245021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study
Lead sponsor
Dr. Eliza Hawkes
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 7, 2017
Completion date
June 30, 2027
Enrollment
39 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma